The Long-Term Safety, Public Health Impact, and Cost-Effectiveness of Routine Vaccination with a Recombinant, Live-Attenuated Dengue Vaccine (Dengvaxia): A Model Comparison Study

BACKGROUND: Large Phase III trials across Asia and Latin America have recently demonstrated the efficacy of a recombinant, live-attenuated dengue vaccine (Dengvaxia) over the first 25 mo following vaccination. Subsequent data collected in the longer-term follow-up phase, however, have raised concern...

Descripción completa

Detalles Bibliográficos
Autores principales: Flasche, Stefan, Jit, Mark, Rodríguez-Barraquer, Isabel, Coudeville, Laurent, Recker, Mario, Koelle, Katia, Milne, George, Hladish, Thomas J., Perkins, T. Alex, Cummings, Derek A. T., Dorigatti, Ilaria, Laydon, Daniel J., España, Guido, Kelso, Joel, Longini, Ira, Lourenco, Jose, Pearson, Carl A. B., Reiner, Robert C., Mier-y-Terán-Romero, Luis, Vannice, Kirsten, Ferguson, Neil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5127514/
https://www.ncbi.nlm.nih.gov/pubmed/27898668
http://dx.doi.org/10.1371/journal.pmed.1002181

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5127514/
https://www.ncbi.nlm.nih.gov/pubmed/27898668
http://dx.doi.org/10.1371/journal.pmed.1002181

Ejemplares similares